Trulieve Cannabis spent the second quarter becoming a different public company. Management deconsolidated the mixed-use Harvest platform so the remaining medical-only perimeter could list on the New York Stock Exchange, the first United States cannabis operator to clear that bar after medical marijuana moved to Schedule III. The listing is the event. The investment debate is whether a cleaner, smaller, federally registered medical operator is a better equity than the old multi-state consolidator, or whether the company simply sold growth markets for a ticker upgrade.
The accounting loss is almost entirely the Harvest write-off. Headline revenue fell because the reporting perimeter shrank mid-quarter, while medical-only sales of $222 million rose sequentially and carried a sixty-three percent gross margin. Adjusted earnings stayed positive at $20 million. Cash of $325 million still funds the platform, but an uncertain tax liability near $598 million sits above that cash pile and remains the unresolved claim from years of Section 280E positioning.
The next several prints resolve a narrower question than the listing story implies. Can medical-only revenue hold near the second-quarter run rate while Georgia pharmacy shipments and a pending Texas license replace the adult-use markets that now sit off the balance sheet? And does retroactive tax relief arrive before that liability has to be funded in cash?